A new market study, titled “Global Oncology Biosimilars Market Research Report 2018”, has been featured on WiseGuyReports.
This report studies the global Oncology Biosimilars market status and forecast, categorizes the global Oncology Biosimilars market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
Oncology biosimilars are similar versions of oncology biologics that are manufactured by different companies and have been officially approved for cancer treatment. Biosimilars are cost-effective molecules with the same efficacy and potency as the original reference biologic. The relatively easy manufacturing of biosimilars and the license to manufacture biosimilars after the expiration of original reference biologic is acting in favor of the global oncology biosimilars market.
Cancer represents a massive burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of several cancer therapeutics has allowed the entry of biosimilars, which are being incorporated into oncology treatment practices. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes. The market offers huge growth opportunities for vendors because of the growing incidence of cancer. The clinical pipeline for cancer biosimilars is vast, featuring candidates in different stages of development. Around 30% of all the biosimilars that are awaiting the US FDA’s approval are monoclonal antibodies, including biosimilars of Avastin, MabThera, and Herceptin.
Factors like the arrival of new biosimilars to drive market growth during the forecast period. Unlike generic drugs, which have APIs that are identical to original drugs, biosimilars are similar to their originator biologic compounds. Biosimilars developed by different manufacturers differ from the original product as well as from each other. Since they are less expensive than biologics, patients will be able to afford and access biosimilars more easily than biologics. Rise in number of patent expiries, increase in prevalence of cancer, growing aging population, promising drug pipeline, need for cost-effective treatment, favorable government regulations are some of the key drivers promoting the growth of oncology biosimilars market.
The major manufacturers covered in this report
Dr Reddy’s Laboratories
F Hoffmann-La Roche
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
We can also provide the customized separate regional or country-level reports, for the following regions:
Rest of Asia-Pacific
Rest of Europe
Central & South America
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Cell Lung Cancer
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
The study objectives of this report are:
To analyze and study the global Oncology Biosimilars sales, value, status (2013-2017) and forecast (2018-2025).
Focuses on the key Oncology Biosimilars manufacturers, to study the sales, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Oncology Biosimilars are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Oncology Biosimilars Manufacturers
Oncology Biosimilars Distributors/Traders/Wholesalers
Oncology Biosimilars Subcomponent Manufacturers
Table of Contents
1 Oncology Biosimilars Market Overview
2 Global Oncology Biosimilars Market Competition by Manufacturers
3 Global Oncology Biosimilars Capacity, Production, Revenue (Value) by Region (2013-2018)
4 Global Oncology Biosimilars Supply (Production), Consumption, Export, Import by Region (2013-2018)
5 Global Oncology Biosimilars Production, Revenue (Value), Price Trend by Type
6 Global Oncology Biosimilars Market Analysis by Application
7 Global Oncology Biosimilars Manufacturers Profiles/Analysis
8 Oncology Biosimilars Manufacturing Cost Analysis
9 Industrial Chain, Sourcing Strategy and Downstream Buyers
10 Marketing Strategy Analysis, Distributors/Traders
11 Market Effect Factors Analysis
12 Global Oncology Biosimilars Market Forecast (2018-2025)
13 Research Findings and Conclusion
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)